Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Study Overview
=================
Brief Summary
-----------------
Open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of TI Inhalation Power in combination with a basal insulin versus insulin aspart in combination with a basal insulin

Detailed Description
-----------------
Phase 3 clinical trial designed to examine the efficacy and safety of inhaled prandial TI Inhalation Power in combination with basal insulin versus insulin aspart in combination with basal insulin in subjects with type 1 diabetes who are suboptimally controlled with their current insulin regimens. This trial will employ a variety of methods to intensively manage these subjects.

Official Title
-----------------
A Phase 3, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With a Basal Insulin Versus Insulin Aspart in Combination With a Basal Insulin in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Conditions
-----------------
Type 1 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Technosphere® Insulin with MedTone C Inhaler
* Drug: Technosphere ®Insulin with Gen2 Inhaler
* Drug: Insulin Aspart in combination with a basal insulin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women = 18 years of age Clinical diagnosis of type 1 diabetes mellitus for at least 12 months Body mass index (BMI) = 38 kg/m2 Stable dose of basal/bolus insulin therapy for at least 3 months with an FPG consistently < 220 mg/dL: HbA1c = 7.5% and = 10.0% Fasting C-peptide = 0.30 pmol/mL Subject willingness to not use CGM during the entire course of the trial Nonsmoking (includes cigarettes, cigars, pipes, and chewing tobacco) for the preceding 6 months Negative urine cotinine test, defined as = 100 ng/mL Lung function tests: • Forced expiratory volume in 1 second (FEV1) = 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted Written informed consent Exclusion Criteria: Total daily insulin dose = 2 IU/kg/day. History of insulin pump use within 3 months of Screening or use of continuous glucose monitoring within 6 weeks of Screening History of inhaled insulin use in the previous 6 months Two or more unexplained severe hypoglycemic episodes within 3 months of Screening or an episode of severe hypoglycemia between Visit 1 and Visit 2. Unexplained refers to episodes of severe hypoglycemia that are not related to a dosing error, lack of or a change in meal size, or related to additional/unanticipated exercise Any hospitalization or emergency room visit due to poor diabetic control within 6 months of Screening, or hospitalization or emergency room visit due to poor diabetic control between Visit 1 and Visit 2 Allergy or known hypersensitivity to insulin or to any of the drugs to be used in the study, or a history of hypersensitivity to TI Inhalation Powder or to drugs with a similar chemical structure History of recent blood transfusions (within previous 3 months), hemoglobinopathies, or any other conditions that affect HbA1c measurements. History of COPD, asthma, or any other clinically important pulmonary disease (eg, pulmonary fibrosis), or use of any medications for these conditions Any clinically significant radiological findings on screening chest x-ray Active respiratory infection within 30 days before Screening (subject may return after 30 days from resolution for rescreening) Major organ system diseases, including: ? Seizure disorder; systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine; cancer (other than excised cutaneous basal cell carcinoma) or any history of lung neoplasms Current or previous chemotherapy or radiation therapy that may result in pulmonary toxicity; use of medications for weight loss (eg, sibutramine, orlistat) within 12 weeks of Screening; treatment with amiodarone within 12 weeks of Screening Clinically significant abnormalities on screening laboratory evaluation or chest x-ray Severe complications of diabetes, in the opinion of the PI, including symptomatic autonomic neuropathy; disabling peripheral neuropathy; active proliferative retinopathy; nephropathy with renal failure, renal transplant, or dialysis; nontraumatic amputations due to gangrene; or vascular claudication Women who are pregnant, lactating, or planning to become pregnant during the clinical study period; women of childbearing potential (defined as premenopausal and not surgically sterilized or postmenopausal for fewer than 2 years) not practicing adequate birth control. Adequate birth control is defined as using oral, percutaneous, or transdermal contraceptives; condoms and diaphragms (double barrier) with a spermicide; or intrauterine devices. Postmenopausal for this study includes amenorrhea f Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the opinion of the PI, would make the subject an unsuitable candidate for participation in the study Exposure to any investigational medications or devices within the previous 30 days before study entry Unable to read or write, or unlikely to comprehend and follow the study protocol procedures; lack of compliance with medication or procedures that, in the PI's opinion, may affect the study data or subject safety and that precludes the subject from participation in the study; or any other concurrent medical or major psychiatric condition that, in the opinion of the PI, makes the subject unsuitable for the clinical study or could limit the validity of the informed consent or impair the subject'

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Technosphere® Insulin with MedTone C Inhaler<br>Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry | Drug: Technosphere® Insulin with MedTone C Inhaler<br>* Inhalation Powder and injectable insulin<br>|
| Active Comparator: Aspart Group<br>Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry | Drug: Insulin Aspart in combination with a basal insulin<br>* Injectable insulin<br>|
| Experimental: Technosphere ® Insulin-Gen2 Group<br>Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry | Drug: Technosphere ®Insulin with Gen2 Inhaler<br>* Inhalation Powder and injectable insulin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline to Week 24 in HbA1c | Effect of treatment as measured by change from baseline in glycated hemoglobin (HbA1c). Primary treatment difference is TI-Gen2 vs. Insulin Aspart at Week 24 | Baseline to Week 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FEV1 Change From Baseline to Week 24 | Forced Expiratory Volume in 1 second - change from baseline to week 24 | Baseline to Week 24 | 
| FPG Change From Baseline to Week 24 | Comparison of mean change from Baseline to Week 24 visit in fasting plasma glucose (FPG) levels (central laboratory results) | Baseline to Week 24 | 
| Mean 7-point Glucose Baseline Values | Mean 7-point glucose at baseline | Baseline | 
| Mean 7-point Glucose Week 24 Values |  | Week 24 | 
| Change in Body Weight From Baseline to Week 24 | Change in body weight from Baseline to Week 24 | Baseline to Week 24 | 
| Proportion of Responders Achieving HbA1c <= 7.0% | Efficacy as measured in proportion of subjects achieving HbA1c < or = to 7.0% | Week 24 |